Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Traws Pharma ( (TRAW) ).
On October 1, 2025, Traws Pharma appointed John Leaman, MD as an independent director and formalized the executive titles of Iain Dukes and Charles Parker as CEO and CFO, respectively. This move, announced on October 6, 2025, highlights the company’s commitment to strong governance and strategic leadership as it progresses with its lead anti-viral product candidate, ratutrelvir, for COVID-19. The appointment of Dr. Leaman, who brings extensive experience in finance and corporate strategy, is expected to provide valuable insights as Traws prepares for Phase 2 studies of ratutrelvir, which could significantly impact the multi-billion dollar COVID treatment market.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases. The company is advancing investigational oral small molecule antiviral agents targeting COVID-19, Long COVID, bird flu, and seasonal influenza.
Average Trading Volume: 108,751
Technical Sentiment Signal: Sell
Current Market Cap: $15.89M
See more data about TRAW stock on TipRanks’ Stock Analysis page.